P/B
0,4
Mustang Bio
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
$3.2M
Market Cap • 10/2/2026
2015
(11 years)
Founded
2017
(9 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,1
EPS
—
Market Cap
Market Cap
3,2M
EV
-12M
EV/Revenue
0
EV/EBITDA
3,4
EV/EBIT
3,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
4,4%
Total Yield
4,4%
Payout
0%
Retained Earnings
-400,7M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-43,4%
CAGR Net Income 5Y
-45,5%
CAGR EPS 5Y
-76,5%
CAGR OCF 5Y
-37,5%
Leverage
N.D./EBITDA
4,3
Debt/Equity
0%
Current Ratio
2
Quick Ratio
1,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!